

RECEIVED
CENTRAL FAX CENTER

Docket No.: PRD-2014USPCT
U.S.S.N. 10/507,084


JAN 16 2009

Listing of Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-27 (cancelled).

28. (previously presented) A compound of formula (I),



the pharmaceutically acceptable addition salts and the stereo-chemically isomeric forms thereof, wherein

t is 0, 1, 2, 3 or 4 and when t is 0 then a direct bond is intended;

each Q is ;

each X is nitrogen;

each Y is nitrogen;

each Z is -NH-, or -O-;

R¹ is -C(O)NR³R⁴, -NHC(O)R⁷, -C(O)-C₁₋₆alkanediylSR⁷, -NR⁶C(O)N(OH)R⁷, -NR⁶C(O)C₁₋₆alkanediylSR⁷, or -NR⁶C(O)C=N(OH)R⁷ wherein R³ and R⁴ are each independently selected from hydrogen, hydroxy, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, aminoC₁₋₆alkyl or aminoaryl;

R⁷ is independently selected from hydrogen, C₁₋₆alkyl, or C₁₋₆alkylcarbonyl;

R⁶ is independently selected from hydrogen or C₁₋₆alkyl;



R² is hydrogen, hydroxy, amino, hydroxyC₁₋₆alkyl, C₁₋₆alkyl, C₁₋₆alkyloxy, arylC₁₋₆alkyl, aminocarbonyl, hydroxycarbonyl, aminoC₁₋₆alkyl,

Docket No.: PRD-2014USPCT
U.S.S.N. 10/507,084

aminocarbonylC₁₋₆alkyl, hydroxycarbonylC₁₋₆alkyl, hydroxyaminocarbonyl,
C₁₋₆alkyloxycarbonyl, C₁₋₆alkylaminoC₁₋₆alkyl or di(C₁₋₆alkyl)aminoC₁₋₆alkyl;

-L- is a bivalent radical selected from -NR⁹C(O)-, -NR⁹SO₂- or -NR⁹CH₂-
wherein R⁹ is hydrogen, C₁₋₆alkyl, C₃₋₁₀cycloalkyl, hydroxyC₁₋₆alkyl,
C₁₋₆alkyloxyC₁₋₆alkyl or di(C₁₋₆alkyl)aminoC₁₋₆alkyl;

... (A) is a radical selected from



wherein each s is independently 0, 1, 2, 3, 4 or 5;

R⁵ is selected from hydrogen or phenyl optionally substituted with one, two or three
substituents independently selected from halo, amino, nitro, C₁₋₆alkyl, C₁₋₆alkyloxy,
hydroxyC₁₋₄alkyl, trifluoromethyl, trifluoromethyloxy, hydroxyC₁₋₄alkyloxy,
C₁₋₄alkylsulfonyl, C₁₋₄alkyloxyC₁₋₄alkyloxy, C₁₋₄alkyloxycarbonyl,
aminoC₁₋₄alkyloxy,
di(C₁₋₄alkyl)aminoC₁₋₄alkyloxy, di(C₁₋₄alkyl)amino, di(C₁₋₄alkyl)aminocarbonyl, di(C₁₋₄
alkyl)aminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkylaminoC₁₋₄alkyl,
di(C₁₋₄alkyl)amino(C₁₋₄alkyl)amino, di(C₁₋₄alkyl)amino(C₁₋₄alkyl)aminoC₁₋₄alkyl,
di(C₁₋₄alkyl)aminoC₁₋₄alkyl(C₁₋₄alkyl)amino,
di(C₁₋₄alkyl)aminoC₁₋₄alkyl(C₁₋₄alkyl)aminoC₁₋₄alkyl,

Docket No.: PRD-2014USPCT
U.S.S.N. 10/507,084

aminosulfonylamino(C₁₋₄alkyl)amino,
aminosulfonylamino(C₁₋₄alkyl)aminoC₁₋₄alkyl,
di(C₁₋₄alkyl)aminosulfonylamino(C₁₋₄alkyl)amino,
di(C₁₋₄alkyl)aminosulfonylamino(C₁₋₄alkyl)aminoC₁₋₆alkyl, cyano,
(hydroxyC₁₋₄alkyl)(C₁₋₄alkyl)amino, (hydroxyC₁₋₄alkyl)(C₁₋₄alkyl)aminoC₁₋₄alkyl,
hydroxyC₁₋₄alkylaminoC₁₋₄alkyl, di(hydroxyC₁₋₄alkyl)aminoC₁₋₄alkyl, hydroxyC₁₋₄alkylamino, di(hydroxyC₁₋₄alkyl)amino, or
di(C₁₋₄alkyl)aminoC₁₋₄alkylamino;

R⁶ is selected from hydrogen; halo; hydroxy; amino; nitro; trihaloC₁₋₆alkyl; trihaloC₁₋₆alkyloxy; C₁₋₆alkyl; C₁₋₆alkyl substituted with aryl and C₃₋₁₀cycloalkyl; C₁₋₆alkyloxy; C₁₋₆alkyloxyC₁₋₆alkyloxy; C₁₋₆alkylcarbonyl; C₁₋₆alkyloxyC₁₋₆alkyl; C₁₋₆alkylsulfonyl; cyanoC₁₋₆alkyl; hydroxyC₁₋₆alkyl; hydroxyC₁₋₆alkyloxy; hydroxyC₁₋₆alkylamino; aminoC₁₋₆alkyloxy; di(C₁₋₆alkyl)aminocarbonyl; di(hydroxyC₁₋₆alkyl)amino; (aryl)(C₁₋₆alkyl)amino; di(C₁₋₆alkyl)aminoC₁₋₆alkyloxy; di(C₁₋₆alkyl)aminoC₁₋₆alkylamino; di(C₁₋₆alkyl)aminoC₁₋₆alkylaminoC₁₋₆alkyl; arylsulfonyl; arylsulfonylamino; aryloxy; aryloxyC₁₋₆alkyl; arylC₂₋₆alkenediyl; di(C₁₋₆alkyl)amino; di(C₁₋₆alkyl)aminoC₁₋₆alkyl; di(C₁₋₆alkyl)amino(C₁₋₆alkyl)amino; di(C₁₋₆alkyl)amino(C₁₋₆alkyl)aminoC₁₋₆alkyl; di(C₁₋₆alkyl)aminoC₁₋₆alkyl(C₁₋₆alkyl)amino; di(C₁₋₆alkyl)aminoC₁₋₆alkyl(C₁₋₆alkyl)aminoC₁₋₆alkyl; aminosulfonylamino(C₁₋₆alkyl)amino; aminosulfonylamino(C₁₋₆alkyl)aminoC₁₋₆alkyl; di(C₁₋₆alkyl)aminosulfonylamino(C₁₋₆alkyl)amino; di(C₁₋₆alkyl)aminosulfonylamino(C₁₋₆alkyl)aminoC₁₋₆alkyl; cyano; (hydroxyC₁₋₆alkyl)(C₁₋₆alkyl)amino; (hydroxyC₁₋₆alkyl)(C₁₋₆alkyl)aminoC₁₋₆alkyl; hydroxyC₁₋₆alkylaminoC₁₋₆alkyl; di(hydroxyC₁₋₆alkyl)aminoC₁₋₆alkyl; phenyl; phenyl substituted with one, two or three substituents independently selected from halo, amino, nitro, C₁₋₆alkyl, C₁₋₆alkyloxy, hydroxyC₁₋₄alkyl, trifluoromethyl, trifluoromethyloxy, hydroxyC₁₋₄alkyloxy, C₁₋₄alkylsulfonyl, C₁₋₄alkyloxyC₁₋₄alkyloxy, C₁₋₄alkyloxyC₁₋₄alkyl, aminoC₁₋₄alkyloxy, di(C₁₋₄alkyl)aminoC₁₋₄alkyloxy, di(C₁₋₄alkyl)amino, di(C₁₋₄alkyl)aminocarbonyl, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, di(C₁₋₄alkyl)aminoC₁₋₄alkylaminoC₁₋₄alkyl,

Docket No.: PRD-2014USPCT

U.S.S.N. 10/507,084

di(C₁₋₄alkyl)amino(C₁₋₄alkyl)amino, di(C₁₋₄alkyl)amino(C₁₋₄alkyl)aminoC₁₋₄alkyl,
 di(C₁₋₄alkyl)aminoC₁₋₄alkyl(C₁₋₄alkyl)amino,
 di(C₁₋₄alkyl)aminoC₁₋₄alkyl(C₁₋₄alkyl)aminoC₁₋₄alkyl,
 aminosulfonylamino(C₁₋₄alkyl)amino,
 aminosulfonylamino(C₁₋₄alkyl)aminoC₁₋₄alkyl,
 di(C₁₋₄alkyl)aminosulfonylamino(C₁₋₄alkyl)amino,
 di(C₁₋₄alkyl)aminosulfonylamino(C₁₋₄alkyl)aminoC₁₋₆alkyl, cyano,
 (hydroxyC₁₋₄alkyl)(C₁₋₄alkyl)amino, (hydroxyC₁₋₄alkyl)(C₁₋₄alkyl)aminoC₁₋₄alkyl,
 hydroxyC₁₋₄alkylaminoC₁₋₄alkyl, di(hydroxyC₁₋₄alkyl)aminoC₁₋₄alkyl,
 hydroxyC₁₋₄alkylamino, di(hydroxyC₁₋₄alkyl)amino, or
 di(C₁₋₄alkyl)aminoC₁₋₄alkylamino;

aryl in the above is phenyl, or phenyl substituted with one or more substituents each
 independently selected from halo, C₁₋₆alkyl, C₁₋₆alkyloxy, trifluoromethyl, cyano or
 hydroxycarbonyl.

29. (previously presented) A compound as claimed in claim 28 wherein

R³ and R⁴ are each independently selected from hydrogen, hydroxy, hydroxyC₁₋₆alkyl,
 aminoC₁₋₆alkyl or aminoaryl;



is a radical selected from (a-1), (a-20), (a-21), (a-28), or (a-29);

R⁵ is selected from hydrogen; phenyl; or phenyl substituted with one, two or three
 substituents independently selected from halo, amino, C₁₋₆alkyl, C₁₋₆alkyloxy,
 hydroxyC₁₋₄alkyl, trifluoromethyl, trifluoromethyloxy, hydroxyC₁₋₄alkyloxy, C₁₋₄
 alkyloxyC₁₋₄alkyloxy,

aminoC₁₋₄alkyloxy,

di(C₁₋₄alkyl)aminoC₁₋₄alkyloxy, di(C₁₋₄alkyl)amino, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, di(C₁₋₄
 alkyl)aminoC₁₋₄alkyl(C₁₋₄alkyl)aminoC₁₋₄alkyl, hydroxyC₁₋₄alkylamino, di(hydroxyC₁₋₄
 alkyl)amino, or

di(C₁₋₄alkyl)aminoC₁₋₄alkylamino.

R⁶ is selected from hydrogen; halo; hydroxy; amino; nitro; trihaloC₁₋₆alkyl; trihaloC₁₋₆
 alkyloxy; C₁₋₆alkyl; C₁₋₆alkyloxy;

C₁₋₆alkyloxyC₁₋₆alkyloxy; C₁₋₆alkylcarbonyl; C₁₋₆alkylsulfonyl; cyanoC₁₋₆alkyl;

hydroxyC₁₋₆alkyl; hydroxyC₁₋₆alkyloxy; hydroxyC₁₋₆alkylamino;

Docket No.: PRD-2014USPCT
U.S.S.N. 10/507,084

aminoC₁₋₆alkyloxy; di(C₁₋₆alkyl)aminocarbonyl; di(hydroxyC₁₋₆alkyl)amino;
arylC₁₋₆alkyl)amino; di(C₁₋₆alkyl)aminoC₁₋₆alkyloxy;
di(C₁₋₆alkyl)aminoC₁₋₆alkylamino; arylsulfonyl; arylsulfonylamino; aryloxy;
arylC₂₋₆alkenediyl; di(C₁₋₆alkyl)amino;
di(C₁₋₆alkyl)aminoC₁₋₆alkyl;
di(C₁₋₆alkyl)aminoC₁₋₆alkyl(C₁₋₆alkyl)aminoC₁₋₆alkyl; cyano; thiophenyl; thiophenyl
substituted with di(C₁₋₆alkyl)aminoC₁₋₆alkyl(C₁₋₆alkyl)aminoC₁₋₆alkyl,
di(C₁₋₆alkyl)aminoC₁₋₆alkyl, or
di(hydroxyC₁₋₆alkyl)aminoC₁₋₆alkyl;
(hydroxyC₁₋₆alkyl)(C₁₋₆alkyl)amino; (hydroxyC₁₋₆alkyl)(C₁₋₆alkyl)aminoC₁₋₆alkyl; or
phenyl optionally substituted with one, two or three substituents independently selected
from halo, amino, C₁₋₆alkyl, C₁₋₆alkyloxy, hydroxyC₁₋₄alkyl, trifluoromethyl,
trifluoromethyloxy, hydroxyC₁₋₄alkyloxy, C₁₋₄alkyloxyC₁₋₄alkyloxy, aminoC₁₋₄alkyloxy,
di(C₁₋₄alkyl)aminoC₁₋₄alkyloxy, di(C₁₋₄alkyl)amino, di(C₁₋₄alkyl)aminoC₁₋₄alkyl, di(C₁₋₄
alkyl)aminoC₁₋₄alkyl(C₁₋₄alkyl)aminoC₁₋₄alkyl,
(hydroxyC₁₋₄alkyl)(C₁₋₄alkyl)amino, (hydroxyC₁₋₄alkyl)(C₁₋₄alkyl)aminoC₁₋₄alkyl,
hydroxyC₁₋₄alkylamino, di(hydroxyC₁₋₄alkyl)amino, or
di(C₁₋₄alkyl)aminoC₁₋₄alkylamino.

30. (previously presented) A compound as claimed in claim 28 wherein t is 0;
R¹ is -C(O)NR³R⁴, -C(O)-C₁₋₆alkanediylSR⁷, -NR⁶C(O)N(OH)R⁷,
-NR⁶C(O)C₁₋₆alkanediylSR⁷ or -NR⁶C(O)C=N(OH)R⁷ wherein R³ and R⁴ are each
independently selected from hydrogen, hydroxy, hydroxyC₁₋₆alkyl or aminoC₁₋₆alkyl; R² is
hydrogen, hydroxy, amino,
hydroxyC₁₋₆alkyl, C₁₋₆alkyl, C₁₋₆alkyloxy, arylC₁₋₆alkyl, aminocarbonyl,
aminoC₁₋₆alkyl, C₁₋₆alkylaminoC₁₋₆alkyl or di(C₁₋₆alkyl)aminoC₁₋₆alkyl;
-L- is a bivalent radical selected from -NHC(O)- or -NHSO₂-;

— is a radical selected from (a-1), (a-20),

(a-21), (a-28), or (a-48);


each s is independently 0, 1, 2, 3 or 4;

R⁵ is hydrogen, phenyl or phenyl substituted with one or two substituents independently
selected from halo, C₁₋₆alkyl, C₁₋₆alkyloxy or trifluoromethyl;

and R⁶ is hydrogen, phenyl; or phenyl substituted with one or two substituents
independently selected from halo, C₁₋₆alkyl, C₁₋₆alkyloxy or trifluoromethyl.

Docket No.: PRD-2014USPCT
U.S.S.N. 10/507,084


31. (previously presented) A compound as claimed in claim 28 wherein t is 0 or 1; each Q


is ; each X is nitrogen; R¹ is -C(O)NH(OH); R² is hydrogen, hydroxy, C₁-6alkyl,

or arylC₁-6alkyl; -L- is a bivalent radical selected from -NHC(O)- or -NHSO₂-;  is a radical selected from (a-1) or (a-20); each s is independently 0 or 1; and each R⁵ is





independently selected from hydrogen or phenyl.

32. (previously presented) A compound as claimed in claim 28 wherein t is 1; each Q is


; each X is nitrogen; each Y is nitrogen; each Z is -O-; R¹ is -C(O)NH(OH); R² is

hydrogen; -L- is a bivalent radical selected from -NHC(O)- or -NHSO₂-;  is a radical selected from (a-1) or (a-20); each s is independently 0 or 1; and each R⁵ is independently selected from hydrogen or phenyl.

33. (currently amended) A compound according to claim 28 selected from the following compounds ~~No 4, No 10, No 8, No 6, No 1, No 12 and No 14~~ :

 <p>Co. No. 4</p>	 <p>Co. No. 10</p>
 <p>Co. No. 8</p>	 <p>Co. No. 6</p>

Docket No.: PRD-2014USPCT
U.S.S.N. 10/507,084



34. (previously presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 28.
35. (currently amended) A pharmaceutical composition combination of anti-cancer agents and a compound of claim 28.
36. (previously presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 33.
37. (currently amended) A pharmaceutical composition combination of anti-cancer agents and a compound of claim 33.